FilingReader Intelligence
Haohai BioTech terminates distribution deal, divests stake
August 20, 2025 at 12:29 PM UTC•By FilingReader AI
Shanghai Haohai Biological Technology's subsidiary terminated its distribution agreement with Hengtai Vision due to Carl Zeiss Vision's planned acquisition of Hengtai Optics.
The company will receive 80 million yuan in termination fees and acquire the remaining 45% equity in Hengtai Vision based on book value as of September 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:688366•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Haohai Biological Technology publishes news
Free account required • Unsubscribe anytime